Losartan to Reverse Sickle Nephropathy

Phase 2 Completed 36 enrolled Children's Hospital Medical Center, Cincinnati

NaSingle-groupOpen-labelTreatment

Summary

Sickle cell disease causes kidney damage with increasing age, leading to chronic kidney disease and renal failure in nearly one third of patients with sickle cell disease. Currently, there is no treatment for sickle cell related kidney disease.

Timeline

Start: 2012-02
Primary completion: 2015-11
Completion: 2015-12

Outcome

Met primary endpoint

paper The primary endpoint was met in 83% of the MacroA group (P < 0.0001) and 58% of the MicroA group (P < 0.0001). PMID 28589652 ↗

Publications

Results Quinn CT, Saraf SL, Gordeuk VR, Fitzhugh CD, Creary SE, Bodas P, George A, Raj AB, Nero AC, Terrell CE, McCord L, Lane A, Ackerman HC, Yang Y, Niss O, Taylor MD, Devarajan P, Malik P. Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. Am J Hematol. 2017 Sep;92(9):E520-E528. doi: 10.1002/ajh.24810. Epub 2017 Jul 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Losartan	Other / unclassified	0.7 mg/kg	Oral
Subject	Losartan	Other / unclassified	50 mg	Oral